CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Income Statement [Abstract]
Net revenues	$ 38,376	$ 17,919	$ 73,256	$ 30,972	$ 82,888
Cost of revenues	13,152	9,797	24,816	17,779	39,870
Impairment of field equipment		6,412		6,412	6,412
Gross profit	25,224	1,710	48,440	6,781	36,606
Operating costs and expenses:
Research, development and clinical trials	9,371	11,318	18,782	22,763	41,467
Sales and marketing	16,360	14,598	31,116	27,906	59,449
General and administrative	15,023	13,031	27,445	25,287	51,007
Total operating costs and expenses	40,754	38,947	77,343	75,956	151,923
Operating loss	(15,530)	(37,237)	(28,903)	(69,175)	(115,317)
Financial expenses, net	(2,183)	(555)	(4,629)	(1,104)	(6,147)
Loss before income tax expense	(17,713)	(37,792)	(33,532)	(70,279)	(121,464)
Income tax expense	3,461	2,820	5,687	5,770	10,381
Net loss	$ (21,174)	$ (40,612)	$ (39,219)	$ (76,049)	$ (131,845)
Basic and diluted net loss per ordinary share	$ (0.24)	$ (0.48)	$ (0.45)	$ (0.90)	$ (1.54)
Weighted average number of ordinary shares used in computing basic and diluted net loss per share	88,218,868	85,274,683	87,835,926	84,843,028	85,558,448